Drugs / GTX 2/3
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT05052398 Comparator | Jan 2021 → Jul 2024 | chemotherapy-induced neuropathy | Algenis SpA | Unknown | No outcome recorded |
| Phase 1/2 | NCT04799041 Comparator | Oct 2019 → Mar 2020 | — | Algenis SpA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GTX 2/3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04799041 ↗ |
| Known as | Gonyautoxin 2/3 | “PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3.” NCT05052398 ↗ |
| Route | Intramuscular | “local intramuscular injection of GTX 2/3” NCT04799041 ↗ |